Your Antidepressant Isn't Working. Your Genes Know Why.

CYP2D6 is one of your liver’s primary antidepressant processors. It is responsible for breaking down SSRIs, SNRIs, tricyclic antidepressants, and many other psychiatric drugs. The enzyme sits in your liver cells and catalyzes the chemical reactions that convert active drug into inactive metabolites your body can eliminate. Without CYP2D6 working properly, psychiatric medications linger in your bloodstream far longer than intended.

CYP2D6 comes in many variants. The most common are normal activity versions (*1), reduced-activity versions (*4, *10), and non-functional versions (*3, *5). Some people carry gene duplications that produce extra copies of the enzyme and dramatically speed metabolism. Poor metabolizers (roughly 7-10% of people with European ancestry) have two non-functional copies. Ultra-rapid metabolizers may have 3-13 copies. A poor metabolizer taking a standard dose accumulates the drug to 4-10 times the expected blood level, causing toxicity; an ultra-rapid metabolizer at the same dose may have virtually no therapeutic effect.

If you have the poor-metabolizer version of CYP2D6, a standard antidepressant dose feels like an overdose. You experience tremor, nausea, sexual dysfunction, emotional blunting, or dizziness within days. If you have the ultra-rapid version, you take the medication as prescribed and feel nothing, no matter how long you wait. Your doctor assumes the drug isn’t for you and tries another. You try a second antidepressant, a third, a fourth, never realizing the problem isn’t the medication; it’s your ability to process it.

CYP2C19 is your liver’s second major pathway for processing antidepressants. It handles citalopram, escitalopram, sertraline, fluoxetine, and many others. Like CYP2D6, it comes in variants that slow, speed, or eliminate the enzyme’s activity. Poor-metabolizer versions (*2, *3) are carried by roughly 2-15% of the population depending on ancestry. Ultra-rapid versions (*17) are more common in certain populations.

When CYP2C19 is slow or absent, SSRIs and SNRIs accumulate in your bloodstream just as they would with a CYP2D6 problem. A poor metabolizer can develop toxic levels at doses another person tolerates easily. The timeline is the same: tremor, nausea, cognitive dulling, sexual side effects, or serotonin syndrome in severe cases. If you’re an ultra-rapid metabolizer, the opposite happens; you clear the drug so quickly that standard doses never reach therapeutic blood levels, and you feel no benefit.

Many people with CYP2C19 variants try multiple SSRIs before discovering the pattern. They switch from citalopram to sertraline because they assume they’re not “SSRI people.” But the problem isn’t the class of drug; it’s the specific enzyme variant they inherited. A poor metabolizer who switches from one CYP2C19-dependent drug to another identical-looking problem is following their doctor’s reasonable advice while ignoring the genetic root.

CYP2C9 is less directly involved in antidepressant metabolism than CYP2D6 or CYP2C19, but it matters for the bigger picture. It processes NSAIDs (which you might take for pain or inflammation), warfarin (if you’re on blood thinners), statins, and some medications often prescribed alongside antidepressants. Variants (*2, *3) reduce enzyme activity. Poor metabolizers represent roughly 5-10% of European ancestry populations.

Why does this matter for your antidepressant regimen? Because you’re likely taking more than one medication, and CYP2C9 variants affect your total metabolic burden. A person with poor CYP2C9 function who is also taking NSAIDs for chronic pain is adding another drug to the liver’s processing queue, potentially slowing down antidepressant metabolism further and increasing the risk of drug interactions. Your antidepressant doesn’t change, but your body’s ability to process it in combination with other medications does.

This is why your pharmacogenomics test should include CYP2C9 even though it’s not the primary antidepressant enzyme. Understanding it helps your doctor see the full metabolic picture and avoid prescribing combinations that stress your liver’s capacity.

VKORC1 codes for vitamin K epoxide reductase, an enzyme that recycles vitamin K in your body. It’s not directly involved in antidepressant metabolism, but it’s critical if you’re taking warfarin (a blood thinner) alongside your antidepressant. The variant -1639G>A affects how efficiently you recycle vitamin K and how sensitive you are to warfarin’s blood-thinning effects. The A allele, carried by roughly 40% of people with European ancestry, reduces vitamin K recycling.

Why mention this in an antidepressant context? Because some antidepressants (particularly SSRIs) have a mild blood-thinning effect of their own, and if you’re also taking warfarin due to heart arrhythmia, clotting history, or other cardiovascular issues, the combination matters. A person with the VKORC1 A allele who starts an SSRI while on warfarin may experience a clinically significant increase in bleeding risk because both drugs thin the blood through different mechanisms. Your doctor needs to know this before prescribing and adjust warfarin dosing accordingly.

This is why pharmacogenomics testing is valuable even for genes that don’t directly metabolize your primary medication. The interactions between your genetic variants and your full medication list create your actual risk profile, not just the drug interaction data sheet.

SLCO1B1 codes for a transporter protein that moves statins from your bloodstream into your liver cells, where they do their work. Variants like *5 (rs4149056, C allele) reduce the efficiency of this transporter. The C allele is carried by roughly 15% of the population. Without efficient transport, statins accumulate in your bloodstream instead of accumulating in your liver, where they’re supposed to lower cholesterol.

This matters for your antidepressant regimen because many people who need psychiatric treatment also need cholesterol management. The SLCO1B1 variant doesn’t directly affect antidepressant metabolism, but it does affect your liver’s overall drug-handling capacity. A person with poor SLCO1B1 function who is taking both an antidepressant and a statin is running a higher risk of statin-related muscle pain (myopathy) because the statin is lingering at higher-than-intended blood levels. Your liver is working to metabolize two drugs that both compete for limited processing resources.

The takeaway is not that you shouldn’t take a statin if you need one. It’s that your pharmacogenomics profile should inform your doctor about the total drug burden your liver is managing, especially if you’re combining psychiatric and cardiovascular medications.

TPMT codes for an enzyme that metabolizes thiopurine drugs like azathioprine and 6-mercaptopurine. These are immunosuppressants used to treat autoimmune conditions such as Crohn’s disease, ulcerative colitis, and rheumatoid arthritis. TPMT variants are rare in the general population (poor metabolizers represent roughly 0.3%), but when they occur, they create a serious problem: the drug accumulates to toxic levels and damages bone marrow, causing dangerous drops in white blood cells and platelets.

Why include TPMT in an antidepressant pharmacogenomics test? Because depression and autoimmune disease co-occur frequently. A person with Crohn’s disease taking azathioprine for immune control also has depression and is starting an antidepressant. TPMT testing ensures that if they have a poor-metabolizer variant, their gastroenterologist knows to drastically reduce the thiopurine dose or switch drugs entirely. Without TPMT testing, a poor metabolizer taking standard thiopurine doses faces bone marrow suppression, a life-threatening complication that can be prevented with dose adjustment.

This is a high-stakes gene because the consequence of ignoring it isn’t poor symptom control; it’s potential hospitalization. If you have any autoimmune condition and are being treated with thiopurines, TPMT testing is not optional; it’s standard of care.